# Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

> **NCT07654231** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Kidney Disease Mineral and Bone Disorder
- Hypertension
- Diabetes
- Dyslipidemia
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Chronic Kidney Disease (Stage 3)

## Interventions

- **DRUG:** Low-dose Colchicine at 0.5mg daily
- **OTHER:** Usual Care

## Key facts

- **NCT ID:** NCT07654231
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654231, "Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07654231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*